Central Nervous System Leukemia
Associated Genetic Biomarkers
NCI Definition: Leukemia infiltrating the central nervous system structures. 
There is 1 clinical trial for central nervous system leukemia, of which 1 is open and 0 are completed or closed. Of the trial that contains central nervous system leukemia as an inclusion criterion, 1 is no phase specified (1 open).
CD19 is the most frequent gene inclusion criterion for central nervous system leukemia clinical trials .
Cyclophosphamide, fludarabine, and tisagenlecleucel are the most common interventions in central nervous system leukemia clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.